You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePentoxifylline
Accession NumberDB00806  (APRD00121)
TypeSmall Molecule
GroupsApproved, Investigational
Description

A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
OxpentifyllineNot AvailableIS
PentoxifilinaSpanishINN
PentoxifyllinGermanINN
PentoxifyllineFrenchINN
PentoxifyllinumLatinINN
PentoxilNot AvailableNot Available
TrentalNot AvailableNot Available
Prescription ProductsNot Available
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pentoxifyllinetablet, extended release400 mgoralTeva Pharmaceuticals USA Inc1998-07-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, film coated, extended release400 mgoralMylan Pharmaceuticals Inc.1997-07-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, film coated, extended release400 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-09-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralMajor Pharmaceuticals2004-02-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralSTAT Rx USA LLC1998-07-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralAidarex Pharmaceuticals LLC1999-06-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralAv Kare, Inc.2013-07-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralPd Rx Pharmaceuticals, Inc.2010-11-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, film coated, extended release400 mgoralMylan Institutional Inc.1998-01-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, film coated, extended release400 mgoralREMEDYREPACK INC.2013-03-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, film coated, extended release400 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, film coated, extended release400 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralPhysicians Total Care, Inc.2003-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralCardinal Health2004-02-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, film coated, extended release400 mgoralCardinal Health2010-07-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, film coated, extended release400 mgoralCardinal Health2009-09-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, film coated, extended release400 mgoralCardinal Health1999-06-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralGolden State Medical Supply, Inc.2001-06-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralApotex Corp.1999-06-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralbryant ranch prepack1999-06-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralAphena Pharma Solutions Tennessee, Llc1999-06-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralOceanside Pharmaceuticals2014-08-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, extended release400 mgoralPreferred Pharmaceuticals, Inc.2012-09-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Pentoxifyllinetablet, film coated, extended release400 mgoralMc Kesson Contract Packaging2012-01-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AgapurinZentiva
Agapurin SRZentiva
An Ruo NingNanjing Yaoda Bio-Pharmaceutical
AngiopentHelcor
Ao Le NiC & O Pharmaceuticals
Ao Nuo HongAosaiKang Pharmaceutical
AotongTreeful Pharmaceutical
AzupentatNot Available
BehrifilSanofi-Aventis
Bo Shu TeJisheng Pharmaceutical
ClaudicatNycomed
DurapentalMylan dura
ElorganSanofi Aventis
EndopentoksasEndokriniai
PentilinKrka
Pentilin RetardKrka
PentofluxBouchara-Recordati
PentofyllinSopharma
PentoksifilinPanfarma
PentolabLamsa
Pentomerratiopharm
PentoxilUpsher-Smith
RentylinAmdipharm
TorentalSanofi-Aventis
TrentalSanofi-Aventis
Trentilin RetardSanta-Farma
Brand mixtures
Brand NameIngredients
Tri-PlenPentoxifylline and Felodipine
SaltsNot Available
Categories
CAS number6493-05-6
WeightAverage: 278.307
Monoisotopic: 278.137890462
Chemical FormulaC13H18N4O3
InChI KeyBYPFEZZEUUWMEJ-UHFFFAOYSA-N
InChI
InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
IUPAC Name
3,7-dimethyl-1-(5-oxohexyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alkaloids and derivatives. These are naturally occurring chemical compounds that contain mostly basic nitrogen atoms. This group also includes some related compounds with neutral and even weakly acidic properties. Also some synthetic compounds of similar structure are attributed to alkaloids. In addition to carbon, hydrogen and nitrogen, alkaloids may also contain oxygen, sulfur and more rarely other elements such as chlorine, bromine, and phosphorus.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassNot Available
Sub ClassNot Available
Direct ParentAlkaloids and derivatives
Alternative Parents
Substituents
  • Alkaloid or derivatives
  • Xanthine
  • Purinone
  • 6-oxopurine
  • Purine
  • Imidazopyrimidine
  • Pyrimidone
  • Pyrimidine
  • N-substituted imidazole
  • Heteroaromatic compound
  • Vinylogous amide
  • Imidazole
  • Azole
  • Urea
  • Lactam
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
PharmacodynamicsPentoxifylline, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Mechanism of actionPentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non selective adenosine receptor antagonist.
AbsorptionNot Available
Volume of distributionNot Available
Protein binding70%
MetabolismNot Available
Route of eliminationExcretion is almost totally urinary; the main biotransformation product is Metabolite V. Essentially no parent drug is found in the urine.
Half life0.4-0.8 hours
ClearanceNot Available
ToxicityLD50=1385 mg/kg(orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9851
Caco-2 permeable-0.5056
P-glycoprotein substrateSubstrate0.595
P-glycoprotein inhibitor INon-inhibitor0.6905
P-glycoprotein inhibitor IIInhibitor0.7157
Renal organic cation transporterNon-inhibitor0.7023
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.6511
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 substrateNon-inhibitor0.9518
CYP450 2D6 substrateNon-inhibitor0.943
CYP450 2C19 substrateNon-inhibitor0.9313
CYP450 3A4 substrateNon-inhibitor0.9827
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.901
Ames testNon AMES toxic0.7131
CarcinogenicityNon-carcinogens0.8965
BiodegradationNot ready biodegradable0.7457
Rat acute toxicity2.4070 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6463
hERG inhibition (predictor II)Non-inhibitor0.8734
Pharmacoeconomics
Manufacturers
  • Actavis elizabeth llc
  • Apotex inc
  • Biovail laboratories inc
  • Heritage pharmaceuticals inc
  • Impax laboratories inc
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Upsher smith laboratories inc
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseoral400 mg
Tablet, film coated, extended releaseoral400 mg
Prices
Unit descriptionCostUnit
TRENtal 400 mg Controlled Release Tabs1.4USD tab
Trental er 400 mg tablet1.27USD tablet
Pentoxifylline powder0.91USD g
Trental 400 mg Sustained-Release Tablet0.88USD tablet
Pentoxifylline 400 mg tablet sa0.71USD tablet
Pentoxifylline CR 400 mg Controlled Release Tabs0.62USD tab
Pentoxil 400 mg Controlled Release Tabs0.62USD tab
Pentoxil er 400 mg tablet0.62USD tablet
Pentoxifylline er 400 mg tablet0.6USD tablet
Apo-Pentoxifylline Sr 400 mg Sustained-Release Tablet0.4USD tablet
Nu-Pentoxifylline-Sr 400 mg Sustained-Release Tablet0.4USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105 °CNot Available
water solubility7.7E+004 mg/L (at 25 °C)MERCK INDEX (1996)
logP0.29BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility5.17 mg/mLALOGPS
logP0.08ALOGPS
logP0.23ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)19.64ChemAxon
pKa (Strongest Basic)-0.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area75.51 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity73.52 m3·mol-1ChemAxon
Polarizability29.27 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General Reference
  1. : European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol. 1996;36(5):315-21. Pubmed
External Links
ATC CodesC04AD03
AHFS Codes
  • 20:24.00
PDB EntriesNot Available
FDA labelDownload (51.7 KB)
MSDSDownload (73.9 KB)
Interactions
Drug Interactions
Drug
AbciximabMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
AcebutololMay enhance the hypotensive effect of Antihypertensives.
AcenocoumarolMay enhance the anticoagulant effect of Vitamin K Antagonists.
Acetylsalicylic acidMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
AliskirenMay enhance the hypotensive effect of Antihypertensives.
AmilorideMay enhance the hypotensive effect of Antihypertensives.
AminophyllineMay increase the serum concentration of Theophylline Derivatives.
AmlodipineMay enhance the hypotensive effect of Antihypertensives.
AnagrelideMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
AtenololMay enhance the hypotensive effect of Antihypertensives.
Azilsartan medoxomilMay enhance the hypotensive effect of Antihypertensives.
BenazeprilMay enhance the hypotensive effect of Antihypertensives.
BendroflumethiazideMay enhance the hypotensive effect of Antihypertensives.
BisoprololMay enhance the hypotensive effect of Antihypertensives.
BumetanideMay enhance the hypotensive effect of Antihypertensives.
CandesartanMay enhance the hypotensive effect of Antihypertensives.
CaptoprilMay enhance the hypotensive effect of Antihypertensives.
CarvedilolMay enhance the hypotensive effect of Antihypertensives.
ChlorothiazideMay enhance the hypotensive effect of Antihypertensives.
ChlorthalidoneMay enhance the hypotensive effect of Antihypertensives.
CilazaprilMay enhance the hypotensive effect of Antihypertensives.
CilostazolMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
CimetidineCimetidine may increase the serum concentration of Pentoxifylline.
CitalopramMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
ClevidipineMay enhance the hypotensive effect of Antihypertensives.
ClonidineMay enhance the hypotensive effect of Antihypertensives.
ClopidogrelMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
DalteparinMay enhance the anticoagulant effect of Heparin (Low Molecular Weight).
DesvenlafaxineMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
DiflunisalMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
DiltiazemMay enhance the hypotensive effect of Antihypertensives.
DipyridamoleMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
DoxazosinMay enhance the hypotensive effect of Antihypertensives.
DuloxetineMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
EnalaprilMay enhance the hypotensive effect of Antihypertensives.
EnoxaparinMay enhance the anticoagulant effect of Heparin (Low Molecular Weight).
EplerenoneMay enhance the hypotensive effect of Antihypertensives.
EprosartanMay enhance the hypotensive effect of Antihypertensives.
EptifibatideMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
EscitalopramMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
EsmololMay enhance the hypotensive effect of Antihypertensives.
Ethacrynic acidMay enhance the hypotensive effect of Antihypertensives.
EtodolacMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
FelodipineMay enhance the hypotensive effect of Antihypertensives.
FenoprofenMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
FloctafenineMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
FluoxetineMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
FluvoxamineMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
FosinoprilMay enhance the hypotensive effect of Antihypertensives.
FurosemideMay enhance the hypotensive effect of Antihypertensives.
GuanfacineMay enhance the hypotensive effect of Antihypertensives.
HeparinPentoxifylline may enhance the anticoagulant effect of Heparin.
HydralazineMay enhance the hypotensive effect of Antihypertensives.
HydrochlorothiazideMay enhance the hypotensive effect of Antihypertensives.
IbuprofenMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
IndapamideMay enhance the hypotensive effect of Antihypertensives.
IndomethacinMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
IrbesartanMay enhance the hypotensive effect of Antihypertensives.
IsradipineMay enhance the hypotensive effect of Antihypertensives.
KetoprofenMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
KetorolacKetorolac (Nasal) may enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased.
LabetalolMay enhance the hypotensive effect of Antihypertensives.
LevomilnacipranMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
LisinoprilMay enhance the hypotensive effect of Antihypertensives.
LosartanMay enhance the hypotensive effect of Antihypertensives.
MannitolMay enhance the hypotensive effect of Antihypertensives.
Mefenamic acidMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
MeloxicamMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
MethyclothiazideMay enhance the hypotensive effect of Antihypertensives.
MethyldopaMay enhance the hypotensive effect of Antihypertensives.
MetolazoneMay enhance the hypotensive effect of Antihypertensives.
MetoprololMay enhance the hypotensive effect of Antihypertensives.
MexiletineCYP1A2 Inhibitors (Strong) may increase the serum concentration of Pentoxifylline.
MilnacipranMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
MoexiprilMay enhance the hypotensive effect of Antihypertensives.
NabumetoneMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
NadololMay enhance the hypotensive effect of Antihypertensives.
NadroparinMay enhance the anticoagulant effect of Heparin (Low Molecular Weight).
NaproxenMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
NebivololMay enhance the hypotensive effect of Antihypertensives.
NifedipineMay enhance the hypotensive effect of Antihypertensives.
NimodipineMay enhance the hypotensive effect of Antihypertensives.
NisoldipineMay enhance the hypotensive effect of Antihypertensives.
NitroprussideMay enhance the hypotensive effect of Antihypertensives.
OlmesartanMay enhance the hypotensive effect of Antihypertensives.
OxaprozinMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
ParoxetineMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
PenbutololMay enhance the hypotensive effect of Antihypertensives.
PerindoprilMay enhance the hypotensive effect of Antihypertensives.
PhenoxybenzamineMay enhance the hypotensive effect of Antihypertensives.
PhentolamineMay enhance the hypotensive effect of Antihypertensives.
PindololMay enhance the hypotensive effect of Antihypertensives.
PiroxicamMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
PrasugrelMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
PrazosinMay enhance the hypotensive effect of Antihypertensives.
PrimaquineCYP1A2 Inhibitors (Strong) may increase the serum concentration of Pentoxifylline.
PropranololMay enhance the hypotensive effect of Antihypertensives.
QuinaprilMay enhance the hypotensive effect of Antihypertensives.
RamiprilMay enhance the hypotensive effect of Antihypertensives.
ReserpineMay enhance the hypotensive effect of Antihypertensives.
SertralineMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
SotalolMay enhance the hypotensive effect of Antihypertensives.
SpironolactoneMay enhance the hypotensive effect of Antihypertensives.
SulindacMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
TelmisartanMay enhance the hypotensive effect of Antihypertensives.
TerazosinMay enhance the hypotensive effect of Antihypertensives.
TheophyllineMay increase the serum concentration of Theophylline Derivatives.
Tiaprofenic acidMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
TicagrelorMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
TiclopidineMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
TinzaparinMay enhance the anticoagulant effect of Heparin (Low Molecular Weight).
TirofibanMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
TolmetinMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
TorasemideMay enhance the hypotensive effect of Antihypertensives.
TrandolaprilMay enhance the hypotensive effect of Antihypertensives.
TriamtereneMay enhance the hypotensive effect of Antihypertensives.
ValsartanMay enhance the hypotensive effect of Antihypertensives.
VenlafaxineMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
VilazodoneMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
VorapaxarMay enhance the antiplatelet effect of Agents with Antiplatelet Properties.
Food Interactions
  • Take with food to reduce irritation. Limit caffeine intake.

Targets

1. cAMP-specific 3',5'-cyclic phosphodiesterase 4B

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
cAMP-specific 3',5'-cyclic phosphodiesterase 4B Q07343 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

2. Adenosine receptor A1

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Adenosine receptor A1 P30542 Details

References:

  1. Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63. Pubmed

3. cGMP-specific 3',5'-cyclic phosphodiesterase

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
cGMP-specific 3',5'-cyclic phosphodiesterase O76074 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

4. cAMP-specific 3',5'-cyclic phosphodiesterase 4A

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
cAMP-specific 3',5'-cyclic phosphodiesterase 4A P27815 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

5. Adenosine receptor A2a

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Adenosine receptor A2a P29274 Details

References:

  1. Kreth S, Ledderose C, Luchting B, Weis F, Thiel M: Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock. 2010 Jul;34(1):10-6. Pubmed

6. 5'-nucleotidase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
5'-nucleotidase P21589 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Ustunsoy H, Sivrikoz MC, Tarakcioglu M, Bakir K, Guldur E, Celkan MA: The effects of pentoxifylline on the myocardial inflammation and ischemia-reperfusion injury during cardiopulmonary bypass. J Card Surg. 2006 Jan-Feb;21(1):57-61. Pubmed

Enzymes

1. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on November 14, 2013 11:35